StockData

Lucid Diagnostics vs PAVmed

LUCD and PAVM side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LUCD and PAVM compare

Lucid Diagnostics is the larger company, worth 6.7 times as much as PAVmed ($81.1M against $12.1M).

Lucid Diagnostics grew revenue faster over the last twelve months (24.9% versus −89.0% for PAVmed).

Lucid Diagnostics keeps more of each dollar of sales as profit, with a net margin of −960% compared with −10795% at PAVmed.

Lucid Diagnostics scores higher on the StockData Score (7 against 6 for PAVmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLUCDPAVM
Size and price
Market cap$81.1M$12.1M
Share price$0.399$1.51
Change, 1 year−62.7%−84.3%
Change, 5 years−95.3%−99.9%
Beta (5Y)1.891.47
Employees823
StockData Score
Total score7 (better)6
Valuation score01 (better)
Growth score2 (better)0
Performance score11
Health score44
Dividend score00
Valuation
P/S14.9× (better)108×
P/B7.4×0.3× (better)
FCF yield–−64.5%
Fair value$0.298–
Margin of safety−33.9%–
Growth
Revenue growth (TTM)24.9% (better)−89.0%
Net income growth (TTM)–−117%
Profitability
Gross margin–−221%
Operating margin−931% (better)−23843%
Net margin−960% (better)−10795%
FCF margin–−6948%
Return on equity−556%−33.3% (better)
Return on invested capital–−65.1%
Financial health
Debt / equity0.000.00
Interest coverage−2815.8× (better)−3338.0×
Current ratio1.33 (better)1.19
Altman Z-score−13.38−11.03 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions30.2%11.7%
Held by insiders24.8%23.5%
Insider net buying, 12 months$245K–
Short interest, % of float9.8%0.21%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.